Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2279-2303
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2279
Table 1 Overexpression of lipogenic enzymes in human tumors
Enzyme nameNeoplasm typeExperimental modelRef.
Fatty acid synthase (FASN)Pancreatic cancerHuman tumor tissue, cell line[96,104,105]
Breast carcinomaHuman tumor tissue[5,9,166]
Prostate cancerHuman tumor tissue[167]
MelanomaHuman tumor tissue[168]
NephroblastomaHuman tumor tissue[169]
Renal cancerCell line[170]
Endometrial carcinomaHuman tumor tissue[12,171]
Colon cancerHuman tumor tissue[11,172]
Ovarian neoplasms squamous cellHuman tumor tissue[10,173]
Carcinoma of the lung head and neck squamousHuman tumor tissue[174]
Cell carcinoma squamous cellHuman tumor tissue[175]
Carcinoma of the tongueHuman tumor tissue[176]
ATP citrate lyase (ACLY)Small cell lung cancerCell line[251]
Bladder cancerHuman tumor tissue[7]
Breast cancerCell line[252]
Gastric cancerHuman tumor tissue, cell line[253]
Colon cancerHuman tumor tissue[254]
Prostate cancerHuman tumor tissue[254]
Hepatocellular carcinomaHuman tumor tissue[255]
Acetyl-CoA carboxylase (ACCA)Prostate cancerHuman tumor tissue[6]
Hepatocellular carcinomaHuman tumor tissue[255]
Breast carcinomaHuman tumor tissue[256]
Stearoyl-CoA desaturase (SCD1)Pancreatic cancerSCD1 indices in patients serum[128]
Clear cell renal cell carcinomaHuman tumor tissue[200]
Acetyl-CoA synthetase (ACS)Colon adenocarcinomaHuman tumor tissue[257]
Malignant gliomaCell line[258]
Citrate synthase (CS)Pancreatic cancerHuman tumor tissue[19]
Renal cell carcinomaHuman tumor tissue[20]
Table 2 Oncogenes and tumor suppressor genes, whose products participate in regulation of cancer cells metabolism
Oncogene/tumor suppressorMetabolic pathwayEnzymeRef.
MYCGlucose transportGLUT1[53-55]
GlycolysisHexokinase 2
Phosphohexose isomerase
Phosphofructokinase 1
Aldolase A
3-phosphoglyceraldehyde dehydrogenase
Phosphoglycerate kinase
Phosphoglycerate mutase
Enolase 1
Pyruvate kinase 2
Lactate dehydrogenase A
Regulation of PDHPyruvate dehydrogenase kinase 1
Glutamine transportGlutamine transporters ASCT2 and SN2
GlutaminolysisGlutaminase 1
Serine hydroxymethyltransferase
Pyrimidine synthesis
Aminoacids metabolismCAD
Ornithine decarboxylase
LipogenesisFatty acid synthase
p53Glucose transportGLUT1[51,56-60]
GlycolysisHexokinase 2
Fructose-2,6-bisphosphatase
Phosphoglycerate mutase
Oxidative phosphorylationCyrochrome c oxidase
GlutaminolysisGlutaminase 2
Pentose Phosphate PathwayGlucose-6-phosphate dehydrogenase
Regulation of PDHPyruvate dehydrogenase kinase 1
Krebs cycleAconitase
KRASGlucose transportGLUT1[61,73,94]
GlycolysisHexokinase 2
Phosphofructokinase 1
Lactate dehydrogenase A
Pentose phosphate pathwayTransketolase
Hexosamine synthesisPhosphohexose aminotransferase
GlutaminolysisGlutamate dehydrogenase
Aspartate transaminase
Akt/PTENGlucose transportGLUT1[50,113-115]
LipogenesisFASN
Table 3 Oncogenes and tumor suppressor genes whose products alter the metabolism of pancreatic cancer cells
GeneProteinMechanism of alteration in PDACRegulated processes in PDACAlteration in PDACRef.
Oncogenes
KRASKRASPoint mutationsCell proliferation and survival, motility, glucose transport, glycolysis, hexosamine synthesis, nonoxidative pentose phosphate pathway arm, glutaminolysis> 95%[73,94,259-261]
AKTAKTMutations, amplificationSignal transduction, lipogenesis, glucose transport10%-20%[73,79-81,262-264]
c-erbB2HER2Overexpression amplificationProliferation, differentiation, survival20%-80%[265-268]
MycMYCAmplification overexpressionGlycolysis, glutaminolysis, PDH inhibition70%[55,73,82,94,269]
Tumor suppressor genes
TP53p53Mutation and second allele deletionCell cycle, apoptosis, DNA repair, glucose transport, glycolysis, lipogenesis, ppp oxidative arm, glutaminolysis50%-80%[270-273]
Smad4/DPC4SMAD4Homozygous deletion, mutation and second allele deletionCell cycle, TGF-β signaling55%[274-276]
STK/LKB1LKB1Homozygous deletion, mutation and second allele deletionApoptosis, lipogenesis, energy production, protein synthesis5%[277-279]
CDKN2A/p16p16Homozygous deletion, mutation, hypermethylationCell cycle95%[280-282]
PTENPTENHypermethylation, inhibition by miRNAPI3K/AKT signaling pathway30%-70%[79,283,284]
Table 4 Most common genetic alterations observed in different types of human pancreatic cancers
Type of pancreatic cancerGene affectedRef.
Pancreatic ductal adenocarcinoma (PDAC)KRAS, AKT, MYC, TP53, SMAD4, CDKN2A, PTEN[55,63,64,73,78,79,94,269,284-287]
(90% of all pancreatic cancers)
Acinar cell carcinoma (ACCA)APC/β-catenin (CTNNB1), BRCA2, BCL10[288-290]
(< 1% of all pancreatic cancers)
Adenosquamous carcinoma (ASC)TP53, CDKN2A, KRAS, E-cadherin,[291,292]
(< 1% of all pancreatic cancers)
Intraductal papillary mucinous neoplasm (IPNM)GNAS, KRAS, RNF4, STK11/LKB1, MUC1, MUC2, hTERT, COX2, Shh[278,293,294]
(1%-3% of all pancreatic cancers)
Mucinous cystic neoplasm (MCN)KRAS, RNF4, TP53, CDKN2A[295]
(< 1% of all pancreatic cancers)
Serous cystadenoma (SCN)VHL[296]
(< 1% of all pancreatic cancers)
Solid-pseudopapillary neoplasm (SPN)APC/β-catenin (CTNNB1), E-cadherin[297,298]
(1%-2% of all pancreatic cancers)
Pancreatic neuroendocrine tumors (PanNET)DAXX, ATRX, MEN1, TSC2, PTEN, PI3KCA, CHGA, CHGB, mTOR[299-302]
(2%-5% of all pancreatic cancers)
Table 5 Lipogenic enzyme inhibitors that can be used as potential antitumor drugs
Enzyme nameInhibitorType of neoplasmRef.
Fatty acid synthase (FASN)CeruleninBreast cancer,[303]
ovarian cancer[304]
C75Breast cancer[216]
Pancreatic cancer[232]
Epigallocatechin-3-gallate (EGG)Prostate cancer[228]
C93Lung cancer[305]
Ovarian cancer[306]
LuteolinBreast cancer, ovarian cancer[228]
Pancreatic cancer[232]
OrlistatProstate cancer[307]
ATP citrate lyase (ACLY)SB-204990 hydroxycitrateLung cancer[308]
Brest cancer[18]
Pancreatic cancer[101]
Acetyl-CoA carboxylase (ACCA)Soraphen A TOFAProstate cancer[309]
Lung cancer, colon cancer[310]
Stearoyl-CoA desaturase (SCD1)CVT-11127 TOFALung cancer[222]
Colon cancer[225]
Acetyl-CoA synthetase (ACS)Triacsin cVarious cancers cell lines[311]